The three QOs qualify cerebrospinal fluid (CSF) biomarkers “low Aβ1-42 and high tau concentrations” as well as “a positive amyloid PET signal” for enrichment in clinical trials for predementia AD and mild to moderate AD (16–18, 24). This evidence concerns the gene MAPT and Alzheimer disease.